Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results From the Phase 2 LEAP-005 Study.
Ponz-Sarvisé M, Rha SY, Gomez-Roca CA, Ortega Morán L, Gill S, Tortora G, Geva R, Saada-Bouzid E, Santoro A, Kim TW, Heudobler D, Dutcus CE, Okpara CE, Ghori R, Zhang Y, Vajdi A, Dettman EJ, Jin F, Groisberg R, Shapira-Frommer R. Ponz-Sarvisé M, et al. Among authors: gomez roca ca. Cancer Res Commun. 2026 Feb 26. doi: 10.1158/2767-9764.CRC-26-0018. Online ahead of print. Cancer Res Commun. 2026. PMID: 41747221
First-in-human phase 1 dose-escalation study of W0180, an anti-VISTA monoclonal antibody, with and without pembrolizumab in patients with locally advanced or metastatic solid tumours.
Gomez-Roca C, Champiat S, Danlos FX, Castañón Álvarez E, Cassier PA, Dupuy E, Jegou D, Primard M, Pétain A, Saccareau M, Gueguen-Dorbes G, Fabre C, Marabelle A, Melero I. Gomez-Roca C, et al. BMJ Oncol. 2026 Feb 17;5(1):e000854. doi: 10.1136/bmjonc-2025-000854. eCollection 2026. BMJ Oncol. 2026. PMID: 41737913 Free PMC article.
HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomas.
Filippini DM, Cabarrou B, Dupain C, Halladjian M, Coquan E, Sablin MP, Mazzarella L, Francisco M, Servant N, Tonini MM, Hundt AF, Castel-Ajgal Z, You B, Bigot F, Ghiringhelli F, Vansteene D, Gomez-Roca C, Cousin S, Lambert A, Saada-Bouzid E, Durando X, Abdeddaim C, Borel C, Chaltiel R, Borcoman E, Legrand F, Bernhart S, Jimenez M, Bièche I, Filleron T, Le Tourneau C, Kamal M, Jeannot E. Filippini DM, et al. Among authors: gomez roca c. ESMO Open. 2026 Jan;11(1):106024. doi: 10.1016/j.esmoop.2025.106024. Epub 2025 Dec 29. ESMO Open. 2026. PMID: 41468684 Free PMC article. Clinical Trial.
Addressing screening failures in early-phase clinical trials in oncology: impact on patient outcomes and strategies for improvement.
Korakis I, Ouali K, Hanvic B, Verlingue L, Allignet B, Lusque A, Clementei S, Magne E, Massard C, Delord JP, Cassier P, Baldini C, Segier B, Gomez-Roca C. Korakis I, et al. Among authors: gomez roca c. ESMO Open. 2025 Aug;10(8):105331. doi: 10.1016/j.esmoop.2025.105331. Epub 2025 Aug 13. ESMO Open. 2025. PMID: 40811880 Free PMC article.
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial.
Borcoman E, Cabarrou B, Francisco M, Bigot F, Ghiringhelli F, Vansteene D, Legrand F, Halladjian M, Dupain C, Le Saux O, Coutzac C, Borel C, Chaltiel R, You B, Gomez-Roca C, Cousin S, Coquan E, Lambert A, Saada-Bouzid E, Durando X, Saint-Ghislain M, Frige G, Guerini-Rocco E, Tonini MM, Bièche I, Castel-Ajgal Z, Marret G, Sablin MP, Jeannot E, Andre F, Filleron T, Jimenez M, Mazzarella L, Servant N, Kamal M, Le Tourneau C. Borcoman E, et al. Among authors: gomez roca c. Nat Cancer. 2025 Aug;6(8):1370-1383. doi: 10.1038/s43018-025-01004-2. Epub 2025 Jun 30. Nat Cancer. 2025. PMID: 40588522 Free PMC article. Clinical Trial.
Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas.
Harrington KJ, Champiat S, Brody JD, Cho BC, Romano E, Golan T, Hyngstrom JR, Strauss J, Oh DY, Popovtzer A, Gomez-Roca C, Perets R, Kim SB, Wong DJ, Powell SF, Khilnani A, Jemielita T, Zhao Q, Zhao R, Ingham M. Harrington KJ, et al. Among authors: gomez roca c. Clin Cancer Res. 2025 Aug 14;31(16):3400-3411. doi: 10.1158/1078-0432.CCR-24-3630. Clin Cancer Res. 2025. PMID: 40499147 Clinical Trial.
ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0).
Cherny NI, Oosting SF, Dafni U, Latino NJ, Galotti M, Zygoura P, Dimopoulou G, Amaral T, Barriuso J, Calles A, Kiesewetter B, Gomez-Roca C, Gyawali B, Piccart M, Passaro A, Roitberg F, Tarazona N, Trapani D, Curigliano G, Wester R, Zarkavelis G, Zielinski C, de Vries EGE. Cherny NI, et al. Among authors: gomez roca c. Ann Oncol. 2025 Aug;36(8):866-908. doi: 10.1016/j.annonc.2025.04.006. Epub 2025 May 22. Ann Oncol. 2025. PMID: 40409995
Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial.
Trédan O, Pouessel D, Penel N, Chabaud S, Gomez-Roca C, Delord JP, Pannier D, Brahmi M, Fabbro M, Garcia ME, Larrieu-Ciron D, Ray-Coquard I, Viala M, Italiano A, Tosi D, Cassier P, Dufresne A, Attignon V, Boyault S, Treilleux I, Viari A, Pérol D, Blay JY. Trédan O, et al. Among authors: gomez roca c. Nat Med. 2025 May;31(5):1502-1508. doi: 10.1038/s41591-025-03613-x. Epub 2025 Apr 7. Nat Med. 2025. PMID: 40195451 Free PMC article. Clinical Trial.
105 results